Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol May Be An Acquisition Target Following Entry Of Plavix Generics

Executive Summary

The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target

You may also be interested in...



Pfizer/Sanofi speculation

Rumors are cropping up regarding potential acquisition of Sanofi-Aventis, or at least a stake in the company, by Pfizer - which has a hefty amount of cash on hand and a pipeline to fill. Sanofi has been the subject of various acquisition rumors, including reports that the company was considering acquiring Plavix (clopidogrel) and Avapro (irbesartan) marketing partner Bristol-Myers Squibb (1"The Pink Sheet" Aug. 14, 2006, p. 3). Merging might not be in the best interest of either company, as both firms' biggest products lose exclusivity in the same timeframe: Pfizer's Lipitor (atorvastatin) in 2010 and Plavix in 2011. Pfizer's recently announced R&D strategy includes working to secure external opportunities in targeted areas through acquisitions, licensing and development, joint venture and alliances and other collaborative agreements (2"The Pink Sheet" Oct. 8, 2007, p. 3)...

Pfizer/Sanofi speculation

Rumors are cropping up regarding potential acquisition of Sanofi-Aventis, or at least a stake in the company, by Pfizer - which has a hefty amount of cash on hand and a pipeline to fill. Sanofi has been the subject of various acquisition rumors, including reports that the company was considering acquiring Plavix (clopidogrel) and Avapro (irbesartan) marketing partner Bristol-Myers Squibb (1"The Pink Sheet" Aug. 14, 2006, p. 3). Merging might not be in the best interest of either company, as both firms' biggest products lose exclusivity in the same timeframe: Pfizer's Lipitor (atorvastatin) in 2010 and Plavix in 2011. Pfizer's recently announced R&D strategy includes working to secure external opportunities in targeted areas through acquisitions, licensing and development, joint venture and alliances and other collaborative agreements (2"The Pink Sheet" Oct. 8, 2007, p. 3)...

Sanofi Tries To Quash Bristol Rumors; M&A Efforts Center On Biotech, Japan

Sanofi-Aventis' merger and acquisition efforts will focus on biotech firms and Japanese companies, CEO Gerard Le Fur maintained Feb. 13

Related Content

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel